News Detail

Treace Medical Q1 net loss widens to $18 million; revenue drops 10% to $47.2 million

PUBT · 4d ago

Listen to the news

Treace Medical Q1 net loss widens to $18 million; revenue drops 10% to $47.2 million

Treace Medical Concepts posted Q1 2026 revenue of USD 47.2 million, down 10%, while net loss widened to USD 18 million, or USD 0.28 per share.
Adjusted EBITDA loss widened to USD 5.5 million from USD 3.8 million.
Cash, cash equivalents, and marketable securities rose to USD 51.9 million at March 31, up USD 3.5 million from year-end, with an additional USD 115 million available under its credit facility subject to conditions.
Initiated a limited market release of SuperBite Compression Screw System, reporting successful first commercial cases, while granted patents surpassed 130 with more than 200 pending applications.
Reaffirmed full-year 2026 revenue guidance of USD 202 million to USD 212 million, projecting an adjusted EBITDA loss of USD 4 million to USD 6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080705PRIMZONEFULLFEED9716214) on May 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.